Specific control molecule in platelets identified07/31/2020
The previously largely unknown molecule bridging integrator 2 (BIN2) plays a central role in platelet activation, as researchers from Würzburg have now shown in a joint project of the DFG Collaborative Research Centre / Transregio 240. This finding provides indications of starting points for drug development against thrombosis, heart attack and stroke and was published in the renowned journal The Journal of Clinical Investigation.
Calcium is an important signaling molecule in virtually all cells. Platelets are activated by calcium and subsequently contribute to hemostasis and wound sealing. However, a misguided activation of blood platelets by uncontrolled calcium signals can also lead to acutely life-threatening events such as thrombosis, heart attacks and strokes, and trigger inflammatory reactions in the blood vessels.
New player of platelet activation identified
Up to now, the molecule stromal interaction molecule 1 (STIM1) has been known as an essential component in the regulation of calcium signals. However, it has this function in many cells of the body and therefore a loss of STIM1 has strong effects such as weakening the immune system. For this reason, it is not suitable as a target structure for drug development.
"In our study, we were able to identify the previously unknown molecule BIN2 as a new interaction partner of STIM1 in platelets and also show that BIN2 also interacts with another component of the calcium machinery," explains Prof. Dr. Bernhard Nieswandt from the Rudolf Virchow Center at the University of Würzburg. The special thing about BIN2 is that it occurs quite specifically in platelets and not, like STIM1, in many other cells. "This enables us to target the platelets precisely, without disrupting the function of other cells," adds PhD student Julia Volz, who had a key role in the study.
The discovery was made possible by the collaboration of several research groups from the Collaborative Research Center Transregio 240, the University of Würzburg and the University Hospital of Würzburg and their wide range of methods. "Using super high-resolution fluorescence microscopy, we were able to show that the molecules STIM1 and BIN2 in the platelet colocalize at certain intervals, thereby substantiating the biochemical data," explains PhD student Charly Kusch, who also played a major role in the work.
Mice without BIN2 are protected from severe courses of the stroke
Mice that do not have BIN2 show significantly reduced calcium signals in the platelets. This leads to smaller blood clots in their blood vessels after damage to the vessel wall, the animals are partially protected against arterial thrombosis and strokes have a milder course. This shows that molecules like BIN2 could be a starting point for drug development against thrombosis, heart attack and stroke. To this end, the exact molecular mechanisms and other interaction partners must now be investigated.
Julia Volz, Charly Kusch, Sarah Beck, Michael Popp, Timo Vögtle, Mara Meub, Inga Scheller, Hannah S. Heil, Julia Preu, Michael K. Schuhmann, Katherina Hemmen, Thomas Premsler, Albert Sickmann, Katrin G. Heinze, David Stegner, Guido Stoll, Attila Braun, Markus Sauer, Bernhard Nieswandt: BIN2 orchestrates platelet calcium signaling in thrombosis and thrombo-inflammation The Journal of Clinical Investigation www.jci.org/articles/view/136457
The research was funded by
The German Research Foundation, the European Union (Thrombo-Inflame, ERDF - European Fund for Regional Development, Bavaria), the German Excellence Initiative to the Graduate School of Life Sciences, University of Würzburg, the Ministry of Culture and Science of the State of North Rhine-Westphalia and the Federal Ministry of Education and Research.
Prof. Dr. Bernhard Nieswandt holds the Chair of Experimental Biomedicine with a focus on Vascular Biology and is head of the Institute for Experimental Biomedicine, which is jointly run by the University Hospital of Würzburg (UKW) and the Rudolf Virchow Center of the Julius-Maximilians-University of Würzburg. He is spokesman of the Collaborative Research Center/Transregio 240, which has been funded by the German Research Foundation since 2018.
Julia Volz was a member of the Nieswandt research group at the Rudolf Virchow Center of the University of Würzburg until May 2020.
Charly Kusch is a researcher in the Nieswandt group at the Rudolf Virchow Center of the University of Würzburg.
About the Rudolf Virchow Center
The Rudolf Virchow Center is a central institution of the University of Würzburg. The research groups are working on target proteins, which are essential for cellular function and therefore central to health and disease.
Prof. Dr. Bernhard Nieswandt (Rudolf Virchow Center, Chair of Experimental Biomedicine, University Hospital Würzburg)
Tel. +49 (0)931 31 80406, firstname.lastname@example.org
Dr. Judith Flurer (Press Office, Rudolf Virchow Center)
Tel. +49 931 31-85822, email@example.com